What is the 13F Pro Quality Score for RIGL?

13F Pro ranks RIGEL PHARMACEUTICALS INC (RIGL) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View RIGL's current score at https://13fpro.ai/company/RIGL (free sign-up required for the full ranking).

Which hedge funds own the most RIGL stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of RIGL include BlackRock,, Soleus Capital Management, L.P., ARMISTICE CAPITAL,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/RIGL as soon as new 13F filings post.

Where does 13F Pro source RIGL data?

All RIGEL PHARMACEUTICALS INC fundamentals and ownership data come directly from SEC EDGAR. RIGEL PHARMACEUTICALS INC files with the SEC under CIK 1034842. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is RIGL in?

RIGEL PHARMACEUTICALS INC (RIGL) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives RIGL's revenue?

Per RIGEL PHARMACEUTICALS INC's latest 10-Q filed with the SEC on 2026-08-04, the biggest revenue drivers are: Product sales, net ($67.0M, +$8.1M YoY); TAVALISSE ($47.4M, +18% YoY); GAVRETO ($10.7M, -10% YoY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/company/RIGL.

What are RIGL's largest expenses?

RIGEL PHARMACEUTICALS INC's latest 10-Q reports these as the largest expense items: Selling, general and administrative ($32.6M, +$3.4M YoY); Research and development ($14.0M, +$7.1M YoY); Cost of product sales ($8.5M, +$4.0M YoY). Sourced directly from SEC EDGAR filing text for Q2 FY2026 (quarter ended June 30, 2026).

How often is RIGL research updated on 13F Pro?

RIGL's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

RIGEL PHARMACEUTICALS INC(RIGL)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1034842 RIGL stock profile & AI dashboard →

13F Pro Quality Score

73.9/100

Rank #125 of 2,961 stocksTOP 5%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

93.9/100

Profitability

99.5/100

Balance Sheet

99.8/100

Earnings Quality

52.0/100

Free Cash Flow

82.6/100

Institutional Flow

49.2/100

Revenue Scale

28.2/100

Dilution Risk

26.8/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why RIGL Scores 74/100

exact factor attribution · 2026-09-11

RIGL's composite is driven by revenue growth and profitability, held back by scale and shareholder dilution. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+8.8 pts

94th pct

Profitability

+7.4 pts

100th pct

Capital efficiency

+5.0 pts

100th pct

Free cash flow

+4.9 pts

83th pct

Earnings growth

+2.1 pts

92th pct

Earnings quality

+0.2 pts

52th pct

Institutional flow

-0.0 pts

49th pct

Shareholder dilution

-1.2 pts

27th pct

Scale

-3.3 pts

28th pct

Latest change (2026-08-04): 74 → 63 · ↓ Free cash flow 78→32; ↓ Revenue growth 94→83

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

Unusual Activity in RIGL

Events flagged as statistical outliers against RIGL's own multi-year baseline — not fixed dollar thresholds.

Score shock2026-08-04
RIGL quality score dropped 11 points (74→63) on a new filing
View source filing →

RIGL Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for RIGEL PHARMACEUTICALS INC (RIGL), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores RIGL at 73.9/100 on a 32-signal composite quality model, placing it at rank #125 of 2,961 stocks — the top 5% of the AI-ranked universe. RIGL scores in the top quartile across balance sheet strength (99.8), profitability (99.5), revenue growth (93.9). Areas of concern include revenue scale (28.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 26.8/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), RIGEL PHARMACEUTICALS INC reports quarterly revenue of $78.7M, net income of $17.3M, an operating margin of 29.9%. Top institutional holders of RIGL by reported 13-F value include BlackRock, Soleus Capital Management, L.P., ARMISTICE CAPITAL, based on the most recent SEC filings. RIGL trades on the Nasdaq exchange and files with the SEC under CIK 1034842. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RIGL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for RIGEL PHARMACEUTICALS INC directly from SEC EDGAR. RIGEL PHARMACEUTICALS INC's 13F Pro composite quality score has ranged between 12 and 79 since 2021, currently 73.9 — an improving long-term trajectory across 68 quarterly and live scoring snapshots.

✦

Fun facts about RIGEL PHARMACEUTICALS INC

Quirks, history, and lore behind RIGL — the kind of stuff that makes a stock memorable.

1
The Basics
A small-cap biopharmaceutical company · headquartered in South San Francisco · listed on Nasdaq · focused on hematology and immunology.
2
The Numbers
Annual revenue in the tens of millions of dollars — typical for a small biotech leaning heavily on a single approved drug to keep the lights on.
3
The History
Founded in the late 1990s during the biotech boom, it spent years developing drugs that target intracellular signaling pathways before finally winning an FDA approval.
4
The Secret
Its core research platform zeroes in on tyrosine kinase inhibition — the same molecular lever pulled by many blockbuster cancer drugs — but its niche is autoimmune blood disorders.
5
The Lore
Its flagship approved product, fostamatinib, treats a rare condition where the immune system attacks platelets — a disease most people can't spell: immune thrombocytopenia.
6
The Giveaway
Named after a dim but real star in the constellation Orion, this South San Francisco biotech sells Tavalisse — the first-in-class SYK inhibitor for chronic ITP.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving RIGL's Business? Latest 10-Q Breakdown

✓ 33/33 datapoints verified

AI-extracted from RIGEL PHARMACEUTICALS INC's 10-Q filed 2026-08-04 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Total revenue fell 23% to $78.7M as a prior-year $40.0M Lilly cost-share release did not repeat, while net product sales rose 14% to $67.0M.

Biggest Revenue Drivers

Product sales, net$67.0M+$8.1M YoY

Improved trends across the portfolio as first-quarter seasonal access-related factors moderated

Contract revenues from collaborations and other$11.7M-$31.0M YoY

Prior-year quarter included $40.0M non-cash release of Lilly cost share liability; current quarter included $4.0M milestone revenue

Biggest Revenue Drivers

Total revenue: $78.7M-23% YoY

Product sales, net$67.0M+$8.1M YoY

Improved trends across the portfolio as first-quarter seasonal access-related factors moderated

Within Product sales, net

TAVALISSE$47.4M+18% YoY

Primarily driven by higher volumes and higher price per bottle, plus lower revenue reserves

GAVRETO$10.7M-10% YoY

Lower volumes and higher revenue reserves, partially offset by higher price per bottle

REZLIDHIA$8.9M+27% YoY

Higher volumes and higher price per bottle, partially offset by higher revenue reserves

Contract revenues from collaborations and other$11.7M-$31.0M YoY

Prior-year quarter included $40.0M non-cash release of Lilly cost share liability; current quarter included $4.0M milestone revenue

Largest Expense Items

Selling, general and administrative$32.6M+$3.4M YoY

Increased personnel-related costs of $2.6M from higher stock-based compensation and other employee costs

Research and development$14.0M+$7.1M YoY

Clinical trial expenses up $2.7M, personnel costs up $2.4M, and $1.5M reimbursable Arvinas/Pfizer development costs

Cost of product sales$8.5M+$4.0M YoY

Product costs up $2.6M on timing of partner drug supply deliveries and higher sales, plus $1.1M higher royalties

Provision for income taxes$6.3M+$5.9M YoY

Federal tax expense of $5.3M recognized after release of the full valuation allowance in Q4 2025

Margins: Cost of product sales nearly doubled to $8.5M as post-approval inventory reflects full manufacturing cost, higher royalties, and partner supply deliveries. Income from operations fell to $23.6M from $61.1M.

Watch Items from the Filing

McKesson accounted for 46% and Cencora 21% of total net product sales and collaboration revenues in the quarter, up from 31% and 12%.
Lilly terminated the collaboration effective June 15, 2026; no future milestones or royalties expected, and Lilly went from 39% of revenue to zero.
Paid $70.0M upfront for VEPPANU license with up to $15.0M more in fees, $60.0M regulatory and $260.0M commercial milestones, plus $40.0M development funding cap.
Cash, equivalents and short-term investments fell to $95.3M from $155.0M; $40.0M drawn on the revolving facility at quarter end, $32.0M repaid in July.
Take-or-pay VEPPANU supply commitment of about $26.8M through 2030, plus $16.3M TAVALISSE manufacturing obligation subject to cancellation fees.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q2 2026

$78.7M

Net Income

Q2 2026

$17.3M

Operating Margin

Q2 2026

29.9%

ROIC

Q2 2026

22.2%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+64.1% YoY

$294.3MFY 2025

FY22 $120.2MFY23 $116.9MFY24 $179.3MFY25 $294.3M

Net Income

+1999.1% YoY

$367.0MFY 2025

FY22 $-58.6MFY23 $-25.1MFY24 $17.5MFY25 $367.0M

Operating Income

+418.6% YoY

$125.5MFY 2025

FY22 $-55.5MFY23 $-20.5MFY24 $24.2MFY25 $125.5M

EPS (Diluted)

+1867.7% YoY

$19.48FY 2025

FY22 $-3.44FY23 $-1.44FY24 $0.99FY25 $19.48

Total Assets

+213.2% YoY

$513.6MFY 2025

FY22 $134.3MFY23 $117.2MFY24 $164.0MFY25 $513.6M

Total Debt

-12.5% YoY

$52.5MFY 2025

FY22 $40.0MFY23 $60.0MFY24 $60.0MFY25 $52.5M

Op. Cash Flow

+140.4% YoY

$75.7MFY 2025

FY22 $-73.8MFY23 $-5.7MFY24 $31.5MFY25 $75.7M

Free Cash Flow

—FY 2025

FY22 $-74.2MFY23 —FY24 —FY25 —

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$294.3M +64.1%	$179.3M +53.4%	$116.9M -2.8%	$120.2M -19.4%	$149.2M +37.4%	$108.6M
Net Income	$367.0M +1999.1%	$17.5M +169.7%	$-25.1M +57.2%	$-58.6M -227.0%	$-17.9M +39.8%	$-29.7M
Operating Income	$125.5M +418.6%	$24.2M +218.1%	$-20.5M +63.1%	$-55.5M -344.5%	$-12.5M +56.9%	$-29.0M
EPS (Diluted)	$19.48 +1867.7%	$0.99 +168.7%	$-1.44 +58.1%	$-3.44 -3027.3%	$-0.11 +38.9%	$-0.18
Total Assets	$513.6M +213.2%	$164.0M +39.9%	$117.2M -12.7%	$134.3M -19.8%	$167.3M +51.6%	$110.4M
Total Debt	$52.5M -12.5%	$60.0M +0.0%	$60.0M +50.0%	$40.0M +100.0%	$20.0M +0.0%	$20.0M
Operating Cash Flow	$75.7M +140.4%	$31.5M +648.0%	$-5.7M +92.2%	$-73.8M -1354.8%	$5.9M +111.3%	$-52.2M
Free Cash Flow	—	—	—	$-74.2M -1513.2%	$5.3M +109.8%	$-53.4M

Get alerted when RIGL's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for RIGEL PHARMACEUTICALS INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of RIGL

BlackRock, Inc.
$75.9M1,939,818 sh
Soleus Capital Management, L.P.
$72.1M1,843,504 sh
ARMISTICE CAPITAL, LLC
$65.4M1,672,000 sh
STATE STREET CORP
$40.7M1,039,994 sh
VANGUARD CAPITAL MANAGEMENT LLC
$30.7M785,107 sh
AMERICAN CENTURY COMPANIES INC
$29.0M741,718 sh
LSV ASSET MANAGEMENT
$28.2M721,666 sh
ACADIAN ASSET MANAGEMENT LLC
$23.1M591,686 sh
D. E. Shaw & Co., Inc.
$21.2M542,539 sh
GEODE CAPITAL MANAGEMENT, LLC
$18.9M483,175 sh

Fund	Value	Shares
BlackRock, Inc.	$75.9M	1,939,818
Soleus Capital Management, L.P.	$72.1M	1,843,504
ARMISTICE CAPITAL, LLC	$65.4M	1,672,000
STATE STREET CORP	$40.7M	1,039,994
VANGUARD CAPITAL MANAGEMENT LLC	$30.7M	785,107
AMERICAN CENTURY COMPANIES INC	$29.0M	741,718
LSV ASSET MANAGEMENT	$28.2M	721,666
ACADIAN ASSET MANAGEMENT LLC	$23.1M	591,686
D. E. Shaw & Co., Inc.	$21.2M	542,539
GEODE CAPITAL MANAGEMENT, LLC	$18.9M	483,175

Companies Similar to RIGL

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

ACAD

ACADIA PHARMACEUTICALS INC

AI score

Similar quality profile · 11 shared holders

Hennion & Walsh Asset Management, Inc.CenterBook Partners LP Virtus Investment Advisers, LLC

IRWD

IRONWOOD PHARMACEUTICALS INC

AI score

Similar quality profile · 11 shared holders

ARMISTICE CAPITAL, LLC SEGALL BRYANT & HAMILL, LLC CM Management, LLC

HRMY

Harmony Biosciences Holdings, Inc.

AI score

Similar quality profile · 15 shared holders

ARMISTICE CAPITAL, LLC LSV ASSET MANAGEMENT Brandywine Global Investment Management, LLC

CPRX

CATALYST PHARMACEUTICALS, INC.

AI score

Similar quality profile · 4 shared holders

LSV ASSET MANAGEMENT Brandywine Global Investment Management, LLC CenterBook Partners LP

INVA

Innoviva, Inc.

AI score

Similar quality profile · 8 shared holders

Brandywine Global Investment Management, LLC LSV ASSET MANAGEMENT SEGALL BRYANT & HAMILL, LLC

KNSA

Kiniksa Pharmaceuticals International, plc

AI score

Similar quality profile · 8 shared holders

Soleus Capital Management, L.P.GLOBEFLEX CAPITAL L P SEGALL BRYANT & HAMILL, LLC

VCYT

VERACYTE, INC.

AI score

Similar quality profile · 6 shared holders

GLOBEFLEX CAPITAL L P SEGALL BRYANT & HAMILL, LLC Soleus Capital Management, L.P.

KRYS

Krystal Biotech, Inc.

AI score

Similar quality profile · 7 shared holders

Soleus Capital Management, L.P.SEGALL BRYANT & HAMILL, LLC OMERS ADMINISTRATION Corp

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put RIGL on your watchlist

Track score changes the day RIGEL PHARMACEUTICALS INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is RIGL a good stock to buy?

13F Pro's AI-powered analysis of RIGEL PHARMACEUTICALS INC (RIGL) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for RIGL are available on the RIGL stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. RIGL is classified as a small company.

Which hedge funds own RIGL?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling RIGL. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of RIGEL PHARMACEUTICALS INC's investment landscape.